Cognitive Impairment in Psychosis: What it is and How it's Treated - A Free Webinar from the Brain & Behavior Research Foundation
July 08, 2021 09:00 ET
|
Brain & Behavior Research Foundation
New York, July 08, 2021 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Cognitive Impairment in Psychosis: What it is and How it's Treated” on...
OWP Pharmaceuticals Announces Patent Issuance for the First-Ever Oral Liquid Suspension of Quetiapine for the Treatment of Schizophrenia and Bipolar Disorder
July 01, 2021 08:00 ET
|
OWP Pharmaceuticals, Inc.
NAPERVILLE, Ill., July 01, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
Outlook on the Precision Psychiatry Global Market to 2026 - Increasing Adoption of Inorganic Growth Strategies is Driving Growth
April 09, 2021 07:58 ET
|
Research and Markets
Dublin, April 09, 2021 (GLOBE NEWSWIRE) -- The "Global Precision Psychiatry Market: Focus on Product Type, Biomarker, Sample, Technology, Applications, End Users, Country Data (15 Countries), and...
Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone
December 01, 2020 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
OWP Pharmaceuticals Announces IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder
October 07, 2020 08:00 ET
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Oct. 07, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
Recent Studies Indicate Brain Training May Provide New Path to Treat Mental Illness
July 14, 2020 08:00 ET
|
Posit Science
SAN FRANCISCO, July 14, 2020 (GLOBE NEWSWIRE) -- Three recently published studies add significant new evidence that brain training exercises may provide a new path for treating schizophrenia – one...
Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
May 29, 2020 09:20 ET
|
Minerva Neurosciences, Inc
The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259,...
Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
May 04, 2020 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
March 24, 2020 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high...
Minerva Neurosciences Announces Completion of Patient Enrollment in Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
February 05, 2020 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet...